2-Bromopyrimidine → HCID 87630283, compound
Reaction equation
[Cl:1][C:2]1[C:7]2[CH:8]=[C:9]([C:11]3[O:15][N:14]=[C:13]([CH2:16][O:17]C4CCNCC4)[N:12]=3)[O:10][C:6]=2[CH:5]=[CH:4][N:3]=1.Br[C:25]1[N:30]=[CH:29][CH:28]=[CH:27][N:26]=1.[CH2:31]1[CH2:41][CH2:40][N:39]2C(=NC[CH2:37][CH2:38]2)CC1>O1CCOCC1>[Cl:1][C:2]1[C:7]2[CH:8]=[C:9]([C:11]3[O:15][N:14]=[C:13]([CH:16]([O:17][N:39]4[CH2:38][CH2:37][CH2:31][CH2:41][CH2:40]4)[C:25]4[N:30]=[CH:29][CH:28]=[CH:27][N:26]=4)[N:12]=3)[O:10][C:6]=2[CH:5]=[CH:4][N:3]=1Participants
Reactant 3
Product 1
Reagents, catalysts & solvents 1
Procedure
A stirred solution of 4-[5-(4-chlorofuro[3,2-c]pyridin-2-yl)-[1,2,4]oxadiazol-3-ylmethoxy]piperidine-1-carboxylic acid tert-butyl ester (Example 57, 150 mg, 346 μmol) in CH2Cl2 (4 mL) was treated with H2O (6 μL) and TFA (1.5 mL). After 1 h, the reaction was concentrated in vacuo, then the excess TFA was removed through azeotropic distillation with PhMe under reduced pressure. The remainder was partitioned between EtOAc and 2M NaOH. The aqueous phase was extracted further with EtOAc, then the combined EtOAc extracts were washed with brine and dried (MgSO4). Filtration and solvent evaporation furnished 4-chloro-2-[3-(piperidin-4-yloxymethyl)-[1,2,4]oxadiazol-5-yl]furo[3,2-c]pyridine: m/z (ES+)=335.1 [M+H]+. A mixture of this amine (105 mg, 315 μmol), 2-bromopyrimidine (55 mg, 346 μmol) and DBU (95 μL, 630 μmol) in dioxane (2 mL) was stirred at ambient temperature for 16 h. The reaction was concentrated and the residue purified by column chromatography (EtOAc-IH, 3:7) to yield the title compound: RT=3.40 min; m/z (ES+)=413.1 [M+H]+.
Workup
- concentrationThe reaction was concentrated
- customthe residue purified by column chromatography (EtOAc-IH, 3:7)
Sources & evidence
- ORD record
- ord-302a415a86c04d5b8fab522330cdb383
- Source dataset
- uspto-grants-2012_06
- Patent number
- US08193359B2
Reaction notes
Loading…